RCEL

Investor Moves

Name	Value	Action	Change	Price	Current Price
Ken GriffinCitadel Advisors $-175.6K TrimQ1 2026 $176k -- $4.12
Ken GriffinCitadel Advisors $127 AddQ4 2025 $127 -- $4.12
Ken GriffinCitadel Advisors $-321.4K TrimQ3 2025 $321k -- $4.12
Ken GriffinCitadel Advisors $84.6K AddQ2 2025 $85k -- $4.12
Ken GriffinCitadel Advisors $-289.3K TrimQ1 2025 $289k -- $4.12
Ken GriffinCitadel Advisors $-165.0K TrimQ4 2024 $165k -- $4.12

Insider Trades

Name	Value	Action	Price	Current Price
Woody Joseph FralinDirector $21k5.2k shares BuyJun 9, 2026 $4.00 $4.12
Woody Joseph FralinDirector $20k5k shares BuyJun 3, 2026 $4.10 $4.12
Woody Joseph FralinDirector $20k5k shares BuyJun 3, 2026 $4.09 $4.12

News

globenewswire.comAVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meetingglobenewswire.comJun 18

seekingalpha.comAVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.comJun 3

seekingalpha.comAVITA Medical, Inc. (RCEL) Discusses Business Progress, Operational Changes and Sequential Revenue Growth Transcriptseekingalpha.comMay 21

globenewswire.comAVITA Medical to Host Investor Webinar Briefingglobenewswire.comMay 17

Trade RCEL

About AVITA Medical, Inc.

AVITA Medical, Inc. is a leading company focused on regenerative tissue, actively commercializing its innovative products across the United States, Australia, and the United Kingdom. The company's mission is to fulfill critical medical needs in areas such as severe burn and trauma injuries, chronic wounds, and various dermatological and aesthetic concerns, including vitiligo. At the core of its operations is a patented and proprietary technology platform that harnesses the natural regenerative properties found within a patient's own skin to develop therapeutic solutions. Their flagship product, the RECELL System, is a sophisticated medical device. It allows healthcare providers to prepare a suspension of "Spray-On Skin" cells directly from a small sample of the patient's healthy skin. This pioneering treatment is primarily approved for use in adults aged eighteen and older who have sustained acute thermal burns. Beyond its commercial activities, AVITA Medical is deeply invested in forward-thinking research. The company has a partnership with the University of Colorado School of Medicine, dedicated to exploring the preclinical viability of a spray-on application for genetically corrected cells. Furthermore, a collaboration with the Houston Methodist Research Institute aims to investigate the molecular processes involved in reversing cellular aging through an advanced cell suspension delivery system. Founded in 2000 and headquartered in Valencia, California, the company previously operated as AVITA Therapeutics, Inc. before officially changing its name to AVITA Medical Inc. in December 2020.

CEO: Cary G. Vance
IPO Date: May 14, 2012

Market Data

Open: $4.01
High: $4.08
Low: $3.92
Volume: 147.2K
Avg Volume: 242K
52W High: $7.12
52W Low: $3.22

Valuation

Market Cap: $100M
Enterprise Value: $93M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-33M
Revenue: $72M
Net Income: $-49M
Cash: $10M
Debt: $46M

Events

EarningsAug 6

EPS est. -0.32